Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.

References

1. Allen M. I., Deslauriers M., Andrews C. W., Tipples G. A., Walters K. A., Tyrrell D. L., Brown N., Condreay L. D. 1998; Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670–1677
   [Google Scholar]
2. Bain V. G., Kneteman N. M., Ma M. M., Gutfreund K., Shapiro J. A., Fischer K., Tipples G., Lee H., Jewell L. D., Tyrrell D. L. 1996; Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62:1456–1462
   [Google Scholar]
3. Bartholomew M. M., Jansen R. W., Jeffers L. J., Reddy K. R., Johnson L. C., Bunzendahl H., Condreay L. D., Tzakis A. G., Schiff E.R., Brown N. A. 1997; Hepatitis -B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments]. Lancet 349:20–22
   [Google Scholar]
4. Ben-Ari Z., Shmueli D., Mor E., Shaharabani E., Bar-Nathan N., Shapira Z., Tur-Kaspa R. 1997a; Beneficial effect of lamivudine pre- and post-liver transplantation for hepatitis B infection. Transplantation Proceedings 29:2687–2688
   [Google Scholar]
5. Ben-Ari Z., Shmueli D., Mor E., Shapira Z., Tur-Kaspa R. 1997b; Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393–396
   [Google Scholar]
6. Buti M., Jardi R., Cotrina M., Rodriguez-Frias F., Esteban R., Guardia J. 1998; Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. Journal of Hepatology 28:510–513
   [Google Scholar]
7. Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., Koike H., Koida I., Arase Y., Saitoh S., Murashima N., Ikeda K., Kumada H. 1998; Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711–1716
   [Google Scholar]
8. Dienstag J. L., Perrillo R. P., Schiff E. R., Bartholomew M., Vicary C., Rubin M. 1995; A preliminary trial of lamivudine for chronic hepatitis B infection [see comments]. New England Journal of Medicine 333:1657–1661
   [Google Scholar]
9. Fu L., Cheng Y. C. 1998; Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(–)SddC (3TC) resistance. Biochemical Pharmacology 55:1567–1572
   [Google Scholar]
10. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A. K., Rolles K., McMaster P., Beranek P., Kennedy F., Kibbler H., McPhillips P., Elias E., Dusheiko G. 1996; Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212–1215
    [Google Scholar]
11. Honkoop P., Niesters H. G., de Man R. A., Osterhaus A. D., Schalm S.W. 1997; Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. Journal of Hepatology 26:1393–1395
    [Google Scholar]
12. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. 1992; Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783–1790
    [Google Scholar]
13. Ladner S. K., Miller T. J., King R. W. 1998; The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3^′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrobial Agents and Chemotherapy 42:2128–2131
    [Google Scholar]
14. Lai C. L., Ching C. K., Tung A. K., Li E., Young J., Hill A., Wong B. C., Dent J., Wu P. C. 1997; Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241–244
    [Google Scholar]
15. Larder B. A., Kemp S. D., Purifoy D. J. 1989; Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proceedings of the National Academy of Sciences, USA 86:4803–4807
    [Google Scholar]
16. Ling R., Harrison T. J. 1997; Production of hepatitis B virus covalently closed circular DNA in transfected cells is independent of surface antigen synthesis. Journal of General Virology 78:1463–1467
    [Google Scholar]
17. Ling R., Mutimer D., Ahmed M., Boxall E. H., Elias E., Dusheiko G. M., Harrison T. J. 1996; Selection of mutations in the hepatitis B virus polymerase during therapy oftransplant recipients with lamivudine. Hepatology 24:711–713
    [Google Scholar]
18. Markowitz J. S., Martin P., Conrad A. J., Markmann J. F., Seu P., Yersiz H., Goss J. A., Schmidt P., Pakrasi A., Artinian L., Murray N. G., Imagawa D. K., Holt C., Goldstein L. I., Stribling R., Busuttil R. W. 1998; Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585–589
    [Google Scholar]
19. Melegari M., Scaglioni P. P., Wands J. R. 1998; Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628–633
    [Google Scholar]
20. Muller R., Samuel D., Fassati L. R., Benhamou J. P., Bismuth H., Alexander G. J. 1994; ‘EUROHEP’ consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. Journal of Hepatology 21:1140–1143
    [Google Scholar]
21. Nevens F., Main J., Honkoop P., Tyrrell D. L., Barber J., Sullivan M. T., Fevery J., De Man R. A., Thomas H. C. 1997; Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258–1263
    [Google Scholar]
22. Niesters H. G., Honkoop P., Haagsma E. B., de Man R. A., Schalm S.W., Osterhaus A. D. 1998; Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. Journal of Infectious Diseases 177:1382–1385
    [Google Scholar]
23. Ono Y., Onda H., Sasada R., Igarashi K., Sugino Y., Nishioka K. 1983; The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Research 11:1747–1757
    [Google Scholar]
24. Schalm S. W., de Man R. A., Heijtink R. A., Niesters H. G. 1995; New nucleoside analogues for chronic hepatitis B. Journal of Hepatology 22:52–56
    [Google Scholar]
25. Tipples G. A., Ma M. M., Fischer K. P., Bain V. G., Kneteman N. M., Tyrrell D. L. 1996; Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo . Hepatology 24:714–717
    [Google Scholar]
26. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. 1993; Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:5653–5656
    [Google Scholar]
27. Toh H., Hayashida H., Miyata T. 1983; Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 305:827–829
    [Google Scholar]
28. Vaudin M., Wolstenholme A. J., Tsiquaye K. N., Zuckerman A. J., Harrison T. J. 1988; The complete nucleotide sequence of the genome of a hepatitis B virus isolated from a naturally infected chimpanzee. Journal of General Virology 69:1383–1389
    [Google Scholar]
29. Wainberg M. A., Salomon H., Gu Z., Montaner J. S., Cooley T. P., McCaffrey R., Ruedy J., Hirst H. M., Cammack N., Cameron J. and others 1995; Development of HIV-1 resistance to (–) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351–357
    [Google Scholar]
30. Wainberg M. A., Hsu M., Gu Z., Borkow G., Parniak M. A. 1996; Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10:S3–10
    [Google Scholar]